Adimab inks discovery deals with Celgene, Innovent
This article was originally published in Scrip
Executive Summary
Adimab signed separate antibody discovery agreements with Celgene and Innovent Biologics less than a month after the Lebanon, New Hampshire-based company licensed its technology platform and separate customized antibody libraries to GlaxoSmithKline and Biogen Idec.